Literature DB >> 16677691

Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study.

Yuzuru Niibe1, Tomoko Kazumoto, Takafumi Toita, Hideya Yamazaki, Keiko Higuchi, Noriko Ii, Kazunori Suzuki, Takashi Uno, Sunao Tokumaru, Makoto Takayama, Kenji Sekiguchi, Yasuo Matsumoto, Koichi Michimoto, Masahiko Oguchi, Kazushige Hayakawa.   

Abstract

OBJECTIVE: In most cases of uterine cervical carcinoma recurrence, the first site of distant metastasis or recurrence is reported to be the para-aortic region. Some reports have demonstrated that, in cases of isolated para-aortic lymph node recurrence treated by radiation therapy, patients survived for a long period, which suggests that isolated para-aortic lymph node recurrence in uterine cervical carcinoma is a regional disease rather than systemic disease. Determining the predictive characteristics of isolated para-aortic lymph node recurrence in patients at the time of the initial treatment for primary uterine cervical carcinoma is important, so we conducted the current multi-institutional study. PATIENTS AND METHODS: Patients (n=3137) with uterine cervical carcinoma of stages Ia to IVa were treated in twelve Japanese hospitals between 1994 and 2003. The current study investigated the frequency and characteristics of patients with isolated para-aortic lymph node recurrence as well as the characteristics of clinical stage, histopathology, serum squamous cell carcinoma antigen level, the treatment method at the initial treatment, the duration between the initial treatment and the recurrence, and the serum squamous cell carcinoma antigen level at the recurrence.
RESULTS: Of the 3137 patients with uterine cervical carcinoma in stages Ia-IVa, 67 (2.1%) experienced recurrence in isolated para-aortic lymph nodes. Stratified by clinical stage, none of the 613 patients with stage Ia experienced recurrence in isolated para-aortic lymph nodes. However, recurrence was experienced by 14 (1.4%) of the 966 patients with stage Ib, 7 (3.5%) of the 199 patients with stage IIa, 14 (2.3%) of the 613 patients with stage IIb, 1 (2.1%) of the 48 patients with stage IIIa, 26 (4.6%) of the 538 patients with stage IIIb, and 5 (5%) of the 100 patients with stage IVa. The mean duration time between the initial treatment and isolated para-aortic recurrence was 20 months (range, 2-49 months). The correlations between duration time and the clinico-pathological factors (clinical stage, histopathology, serum squamous cell carcinoma antigen level, and treatment method) at the initial treatment were investigated. No statistically significant factors have been revealed in the current study.
CONCLUSIONS: The frequency of isolated para-aortic lymph node recurrence was 2.1% and increased with increasing clinical stage at the initial treatment (stage IVa: 5%) in the current study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677691     DOI: 10.1016/j.ygyno.2006.03.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  18 in total

1.  Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.

Authors:  Eng-Yen Huang; Yu-Jie Huang; Chan-Chao Chanchien; Hao Lin; Chong-Jong Wang; Li-Min Sun; Chin-Wen Tseng; Ching-Chou Tsai; Yu-Che Ou; Hung-Chun Fu; Hui-Chun Chen; Hsuan-Chih Hsu; Chang-Yu Wang
Journal:  Radiat Oncol       Date:  2012-01-30       Impact factor: 3.481

2.  Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer.

Authors:  Wan Jeon; Hyeon Kang Koh; Hak Jae Kim; Hong-Gyun Wu; Jin Ho Kim; Hyun Hoon Chung
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

3.  An 87-year-old patient with repeated oligorecurrences over six years whose disease were treated with radiotherapy alone.

Authors:  Hyong Geun Yun
Journal:  Radiat Oncol J       Date:  2014-12-30

Review 4.  Oligometastases and oligo-recurrence: the new era of cancer therapy.

Authors:  Yuzuru Niibe; Kazushige Hayakawa
Journal:  Jpn J Clin Oncol       Date:  2010-01-04       Impact factor: 3.019

5.  Novel insights of oligometastases and oligo-recurrence and review of the literature.

Authors:  Yuzuru Niibe; Joe Y Chang
Journal:  Pulm Med       Date:  2012-08-22

6.  Cancer of the pelvis: definitive three-dimensional conformal radiotherapy for patients with isolated recurrence in the para-aortic lymph nodes.

Authors:  Katsuya Yahara; Takayuki Ohguri; Hajime Imada; Shinsaku Yamaguchi; Hiromi Terashima; Yukunori Korogi
Journal:  J Radiat Res       Date:  2012-07-22       Impact factor: 2.724

7.  Stereotactic body radiotherapy for metachronous multisite oligo-recurrence: a long-surviving case with sequential oligo-recurrence in four different organs treated using locally radical radiotherapy and a review of the literature.

Authors:  Hiroshi Onishi; Masatoki Ozaki; Kengo Kuriyama; Takafumi Komiyama; Kan Marino; Masayuki Araya; Ryo Saito; Shinichi Aoki; Yoshiyasu Maehata; Licht Tominaga; Mitsuhiko Oguri; Iori Watanabe; Kojiro Onohara; Meguru Watanabe; Naoki Sano; Tsutomu Araki
Journal:  Pulm Med       Date:  2012-10-23

8.  Oligometastases/Oligo-recurrence of lung cancer.

Authors:  Yuzuru Niibe; Joe Y Chang; Hiroshi Onishi; Joseph Salama; Takao Hiraki; Hideomi Yamashita
Journal:  Pulm Med       Date:  2013-02-14

9.  Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases.

Authors:  Wataru Takahashi; Hideomi Yamashita; Yuzuru Niibe; Kenshiro Shiraishi; Kazushige Hayakawa; Keiichi Nakagawa
Journal:  Pulm Med       Date:  2012-10-04

10.  Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence.

Authors:  Tetsuya Inoue; Norio Katoh; Rikiya Onimaru; Hiroki Shirato
Journal:  Pulm Med       Date:  2012-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.